World Pharma News via MedWorm.com MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'World Pharma News' source. Tue, 19 Oct 2010 17:23:06 +0100 GlaxoSmithKline and Human Genome Sciences announce FDA priority review designation for Benlysta® http://www.medworm.com/index.php?rid=3883707&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1338%2F32%2F GlaxoSmithKline PLC (GSK) and Human Genome Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted a priority review designation to Benlysta® (belimumab) as a potential treatment for systemic lupus erythematosus (SLE). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3883707 Thu, 19 Aug 2010 23:00:00 +0100 3883707 Ipilimumab Receives FDA Priority Review Designation http://www.medworm.com/index.php?rid=3879038&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1337%2F32%2F Bristol-Myers Squibb Company (NYSE: BMY) has announced that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review, the Biologics License Application (BLA) for ipilimumab for the treatment of adult patients with advanced melanoma who have been previously treated. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3879038 Wed, 18 Aug 2010 23:00:00 +0100 3879038 Lilly Halts Development of Semagacestat for Alzheimer's Disease http://www.medworm.com/index.php?rid=3874798&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1336%2F29%2F Eli Lilly and Company (NYSE: LLY) will halt development of semagacestat, a gamma secretase inhibitor being studied as a potential treatment for Alzheimer's disease, because preliminary results from two ongoing long-term Phase III studies showed it did not slow disease progression and was associated with worsening of clinical measures of cognition and the ability to perform activities of daily living. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3874798 Tue, 17 Aug 2010 23:00:00 +0100 3874798 International Society for Cellular Therapy (ISCT) launches Cell Therapy Industry Partnership http://www.medworm.com/index.php?rid=3870918&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1334%2F27%2F Many companies in the cell therapy regenerative medicine market including Roche, Genzyme, Athersys, Miltenyi Biotec, Hospira, Lonza and Life Technologies will join ISCT to launch a series of new initiatives that will create greater strategic alignment within the industry and drive late stage clinical development. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3870918 Mon, 16 Aug 2010 23:00:00 +0100 3870918 FDA Proposes Withdrawal of Low Blood Pressure Drug http://www.medworm.com/index.php?rid=3870917&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1335%2F32%2F The U.S. Food and Drug Administration proposed to withdraw approval of the drug midodrine hydrochloride, used to treat the low blood pressure condition orthostatic hypotension, because required post-approval studies that verify the clinical benefit of the drug have not been done. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3870917 Mon, 16 Aug 2010 23:00:00 +0100 3870917 Data on Electronic Sampling, Online Promotion, Tech-Enabled Reps, Customer Service, and iPads http://www.medworm.com/index.php?rid=3868075&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1333%2F27%2F Pharmaceutical and healthcare market research company Manhattan Research releases the tenth version of ePharma Physician®, its study focused on physicians connecting with pharmaceutical and biotech companies through the Internet, tech-enabled reps, and online promotion. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3868075 Sun, 15 Aug 2010 23:00:00 +0100 3868075 Lundbeck reports strongly increasing profits with EBIT growth of 30% http://www.medworm.com/index.php?rid=3863883&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1332%2F31%2F H. Lundbeck A/S (Lundbeck) reports second quarter revenue of DKK 3,767 million. An increase of 7% compared to the second quarter results of 2009. Profit from operations was DKK 936 million, an increase of 30% compared to the same period last year. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3863883 Fri, 13 Aug 2010 23:00:00 +0100 3863883 Abbott Launches New Psoriasisanswers.com Web site http://www.medworm.com/index.php?rid=3860467&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1331%2F27%2F August marks National Psoriasis Awareness Month, an opportunity to raise awareness about psoriasis, a skin disease that affects nearly 7.5 million Americans. For those living with this condition, finding information about what's happening to them can be a challenge. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3860467 Thu, 12 Aug 2010 23:00:00 +0100 3860467 Pharma Marketing 2010 - Frankfurt http://www.medworm.com/index.php?rid=3856792&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1330%2F28%2F 30 September 2010, Frankfurt, Germany. Pharma Marketing 2010 in Frankfurt provides a key platform for Europe's pharmaceutical industry stakeholders, such as yourself, to discover how best to tackle the key challenges of a price-sensitive and increasingly competitive and rapidly changing market. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3856792 Wed, 11 Aug 2010 23:00:00 +0100 3856792 EMA and US FDA seek potential candidate companies for joint GMP inspection programme http://www.medworm.com/index.php?rid=3856791&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1329%2F27%2F The European Medicines Agency (EMA) and the Food and Drug Administration of the United States of America (US FDA) continue to seek potential candidate companies for a joint GMP inspection pilot programme for manufacturers of medicinal products. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3856791 Wed, 11 Aug 2010 23:00:00 +0100 3856791 Amgen Announces Top-Line Results of Phase 3 Head and Neck Cancer Trial http://www.medworm.com/index.php?rid=3856793&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1328%2F29%2F Amgen (Nasdaq: AMGN) today announced top-line results from a randomized Phase 3 trial evaluating Vectibix(R) (panitumumab) as a first-line treatment in patients with recurrent and/or metastatic squamous cell head and neck cancer. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3856793 Tue, 10 Aug 2010 23:00:00 +0100 3856793 Pfizer Reports Second-Quarter 2010 Results http://www.medworm.com/index.php?rid=3852226&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1327%2F31%2F Pfizer Inc. (NYSE: PFE) has reported financial results for second-quarter 2010. Since the acquisition of Wyeth was completed on October 15, 2009, legacy Wyeth products and operations are reflected in the first two quarters of 2010, but not reflected in the first two quarters of 2009. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3852226 Tue, 10 Aug 2010 23:00:00 +0100 3852226 Scientists find 95 genetic variants associated with heart disease risk factor http://www.medworm.com/index.php?rid=3847280&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1326%2F27%2F An international team of scientists has identified 95 genetic variants associated with high blood cholesterol and triglyceride levels which are major risk factors for coronary heart disease. The study, published in the journal Nature and funded in part by the EU, could lead to novel ways of preventing and treating heart disease. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3847280 Mon, 09 Aug 2010 23:00:00 +0100 3847280 Clinical Trials 2010 - Frankfurt http://www.medworm.com/index.php?rid=3838819&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1324%2F28%2F 29 - 30 September 2010, Frankfurt, Germany. In the current environment where minimising cost and delivering ROI are critical themes within the pharma industry, improving your clinical trial infrastructure can ensure that time is not wasted and you are maximising your investments. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3838819 Sun, 08 Aug 2010 23:00:00 +0100 3838819 Image of new antibiotic in action opens up new opportunities http://www.medworm.com/index.php?rid=3838818&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1325%2F27%2F Detailed pictures showing how a new type of experimental antibiotic can kill bacteria already resistant to existing treatments.(1) The findings could ultimately help scientists to develop new antibiotics to tackle the bacteria responsible for many hospital and community-acquired infections. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3838818 Sun, 08 Aug 2010 23:00:00 +0100 3838818 TEMPO study further demonstrates the benefits of Azilect® in early Parkinson's disease patients http://www.medworm.com/index.php?rid=3825682&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1323%2F29%2F H. Lundbeck A/S (Lundbeck) and Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) have announced newly published long-term data on Azilect® (rasagiline tablets) from the TEMPO study and its open-label extension. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3825682 Thu, 05 Aug 2010 23:00:00 +0100 3825682 Genzyme and Isis Report Results of Two Phase 3 Trials of Mipomersen http://www.medworm.com/index.php?rid=3819340&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1322%2F29%2F Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced results of two phase 3 studies of mipomersen in patients who had high cholesterol levels while on maximally tolerated lipid-lowering therapy. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3819340 Wed, 04 Aug 2010 23:00:00 +0100 3819340 Shire Proposes to Expand Specialist Gastrointestinal Portfolio http://www.medworm.com/index.php?rid=3814799&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1321%2F31%2F Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that a Luxembourg incorporated wholly-owned subsidiary of Shire plc will launch a voluntary public takeover offer for all the shares in Movetis NV, the Belgium-based European specialty gastrointestinal (GI) company. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3814799 Tue, 03 Aug 2010 23:00:00 +0100 3814799 Scientists launch new attack against AIDS http://www.medworm.com/index.php?rid=3811225&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1320%2F27%2F EU-funded researchers have developed a new defence against infection from the AIDS (acquired immune deficiency syndrome) virus. The pioneering method involves creating a protective shield that restricts the virus from making contact with a susceptible host cell and penetrating the immune system. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3811225 Mon, 02 Aug 2010 23:00:00 +0100 3811225 AstraZeneca Second Quarter and Half Year Results 2010 http://www.medworm.com/index.php?rid=3808245&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1319%2F31%2F Revenue in the second quarter increased by 1 percent at CER, but was up 3 percent on an actual basis as a result of the positive impact of exchange rate movements. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3808245 Sun, 01 Aug 2010 23:00:00 +0100 3808245 Bayer increases sales and earnings in the second quarter http://www.medworm.com/index.php?rid=3800925&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1318%2F31%2F Sales of the Bayer Group rose by 14.6 percent in the second quarter, to EUR 9,179 million (Q2 2009: EUR 8,009 million). Adjusted for currency and portfolio effects, business grew by 9.2 percent. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3800925 Thu, 29 Jul 2010 23:00:00 +0100 3800925 FDA Grants Priority Review to Cladribine Tablets http://www.medworm.com/index.php?rid=3797096&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1317%2F32%2F Merck KGaA announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Cladribine Tablets as a therapy for relapsing forms of multiple sclerosis (MS). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3797096 Wed, 28 Jul 2010 23:00:00 +0100 3797096 Lilly Reports Strong Second-Quarter 2010 Results http://www.medworm.com/index.php?rid=3792687&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1316%2F31%2F Eli Lilly and Company (NYSE: LLY) announced financial results for the second quarter of 2010. In the second quarter of 2010, worldwide total revenue was $5.749 billion, an increase of 9 percent compared with the second quarter of 2009. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3792687 Tue, 27 Jul 2010 23:00:00 +0100 3792687 Sanofi-aventis expresses concern over the approval of another version of enoxaparin sodium http://www.medworm.com/index.php?rid=3788938&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1315%2F32%2F Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) has reservations on approval by the U.S. Food and Drug Administration (FDA) of another version of enoxaparin sodium. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3788938 Mon, 26 Jul 2010 23:00:00 +0100 3788938 Tracking down neuromuscular diseases http://www.medworm.com/index.php?rid=3788939&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1314%2F27%2F Neuromuscular diseases (NMDs) are chronic and so far incurable conditions that gradually affect patients' muscles, leading to potentially severe disabilities. Biomedical researchers are busy looking for the diseases' Achilles' heel. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3788939 Sun, 25 Jul 2010 23:00:00 +0100 3788939 Sandoz leads the way with first generic version of 'gold standard' anti-thrombotic Lovenox® http://www.medworm.com/index.php?rid=3786659&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1313%2F32%2F Sandoz announced the introduction of enoxaparin sodium injection, the first generic version of Lovenox®[1], in the US. Product shipment began immediately following approval by the US Food and Drug Administration (FDA). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3786659 Sun, 25 Jul 2010 23:00:00 +0100 3786659 Roche posts good half year results http://www.medworm.com/index.php?rid=3782631&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1312%2F31%2F The Roche Group posted strong operating results in the first half of 2010. Group sales grew by 5% in local currencies (3% in Swiss francs; 7% in US dollars) to 24.6 billion Swiss francs. The Pharmaceuticals Division increased its sales by 4% in local currencies (1% in Swiss francs; 6% in US dollars) to 19.4 billion Swiss francs. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3782631 Fri, 23 Jul 2010 23:00:00 +0100 3782631 Bristol-Myers Squibb Second Quarter Featured Robust Clinical Data and Double-Digit EPS Growth http://www.medworm.com/index.php?rid=3778925&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1310%2F31%2F Bristol-Myers Squibb Company (NYSE: BMY) reported results for the second quarter of 2010 which featured data on key marketed and investigational compounds in its oncology, diabetes and cardiovascular franchises, and growth in sales and EPS. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3778925 Thu, 22 Jul 2010 23:00:00 +0100 3778925 Pfizer to Offer Free Public Access to Mental Health Assessment Tools http://www.medworm.com/index.php?rid=3778924&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1311%2F27%2F As part of its commitment to improving the quality of patient care, Pfizer (NYSE: PFE) will make available assessment scales used by physicians and others in the healthcare community to support the evaluation and diagnosis of patients suffering from certain mental disorders. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3778924 Thu, 22 Jul 2010 23:00:00 +0100 3778924 GlaxoSmithKline statement in response to FDA announcement on TIDE trial http://www.medworm.com/index.php?rid=3774747&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1309%2F29%2F GlaxoSmithKline [NYSE: GSK] confirmed that it will suspend enrollment of new patients in the Thiazolidinedione Intervention with Vitamin D Evaluation (TIDE) clinical trial at the request of the U.S. Food and Drug Administration (FDA) pending FDA review of recommendations from its Advisory Committee meeting July 13-14. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3774747 Wed, 21 Jul 2010 23:00:00 +0100 3774747 Abbott Reports Strong Second Quarter Results http://www.medworm.com/index.php?rid=3774748&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1308%2F31%2F Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2010. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3774748 Tue, 20 Jul 2010 23:00:00 +0100 3774748 U.S. Nurses Believe They Considerably Influence Patient Health Decisions and Behavior http://www.medworm.com/index.php?rid=3770450&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1307%2F27%2F According to pharmaceutical and healthcare market research company Manhattan Research, U.S. nurses believe they considerably influence patients' health decisions and behavior. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3770450 Tue, 20 Jul 2010 23:00:00 +0100 3770450 Novartis delivers strong financial performance in second quarter http://www.medworm.com/index.php?rid=3766132&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1306%2F31%2F Novartis delivered a strong performance in the second quarter of 2010 - with the rapid expansion of recently launched products and important regulatory approvals achieved for new medicines - as the Group made progress on its agenda on innovation, growth and productivity. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3766132 Mon, 19 Jul 2010 23:00:00 +0100 3766132 Bayer Schering Pharma enters strategic partnership with Hospital in China http://www.medworm.com/index.php?rid=3766133&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1305%2F30%2F Bayer Schering Pharma AG, Germany, has entered into a research collaboration agreement with The People's Liberation Army General Hospital (301 Hospital) in Beijing, China. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3766133 Sun, 18 Jul 2010 23:00:00 +0100 3766133 FDA Grants Priority Review Designation to Denosumab http://www.medworm.com/index.php?rid=3763810&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1304%2F32%2F Amgen (Nasdaq: AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted priority review designation to denosumab, a subcutaneous RANK Ligand inhibitor, for the treatment of bone metastases to reduce skeletal related events (SREs) in patients with cancer. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3763810 Sun, 18 Jul 2010 23:00:00 +0100 3763810 Mylan to Acquire Bioniche Pharma Global Injectable Pharmaceuticals Business http://www.medworm.com/index.php?rid=3756304&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1303%2F31%2F Mylan Inc. (Nasdaq: MYL) has announced plans to acquire Bioniche Pharma Holdings Limited, a privately held, global injectable pharmaceutical company for $550 million in cash. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3756304 Thu, 15 Jul 2010 23:00:00 +0100 3756304 Amgen Foundation and Changemakers Launch Global Online Competition to Empower Patients http://www.medworm.com/index.php?rid=3752405&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1301%2F27%2F The Amgen Foundation is supporting an online competition with Ashoka's Changemakers to find the best solutions that elevate patients' voices to improve health outcomes globally. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3752405 Wed, 14 Jul 2010 23:00:00 +0100 3752405 European Medicines Agency starts review of rosiglitazone-containing medicines http://www.medworm.com/index.php?rid=3752404&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1302%2F27%2F The European Medicines Agency has started a review of the rosiglitazone-containing anti-diabetes medicines Avandia, Avandamet and Avaglim, to determine whether new data on the risk of cardiovascular problems have an impact on their benefit-risk profile. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3752404 Wed, 14 Jul 2010 23:00:00 +0100 3752404 GlaxoSmithKline (GSK) responds to Senate Finance Committee letter http://www.medworm.com/index.php?rid=3748652&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1300%2F32%2F The Senate Finance Committee (SFC) has released a small subset of the 14 million pages of documents provided to plaintiffs' counsel in the product liability litigation. They include drafts and other documents taken out of context, which therefore are incomplete and misleading. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3748652 Tue, 13 Jul 2010 23:00:00 +0100 3748652 Pfizer Strengthens Manufacturing Capabilities in Asia http://www.medworm.com/index.php?rid=3745532&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1299%2F30%2F Pfizer Inc. (NYSE: PFE) announced a $100 million (U.S.) investment into the expansion of its Singapore Nutrition Plant, helping it continue to set the standard for the manufacture of high-quality, safe and environmentally sustainable nutritional products for infants and children. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3745532 Mon, 12 Jul 2010 23:00:00 +0100 3745532 6th Annual Future of Clinical Trials http://www.medworm.com/index.php?rid=3745533&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1298%2F28%2F 26 - 27 October 2010, Vienna, Austria. Leading Pharmaceutical players understand, how to complete trials with greater levels of cost-efficiency, timelines and success. Reveal, how to tailor clinical trials to the needs of the patients. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3745533 Sun, 11 Jul 2010 23:00:00 +0100 3745533 Data support Avandia (rosiglitazone maleate) cardiovascular safety profile http://www.medworm.com/index.php?rid=3743159&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1297%2F32%2F The U.S. Food and Drug Administration (FDA) posted a comprehensive review conducted by GlaxoSmithKline (GSK) of the cardiovascular safety data on Avandia® (rosiglitazone maleate). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3743159 Sun, 11 Jul 2010 23:00:00 +0100 3743159 Testing for Human Papillomavirus Genotypes 16 and 18 Detects Cervical Pre-Cancer Missed by Pap Test http://www.medworm.com/index.php?rid=3735643&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1296%2F29%2F Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that data from the ATHENA (Addressing THE Need for Advanced HPV Diagnostics) U.S. registration trial of over 47,000 women demonstrate that two human papillomavirus genotypes, HPV 16 and HPV 18, can identify those women with cervical pre-cancer missed by cytologic examination with a Papanicolau (Pap) test. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3735643 Thu, 08 Jul 2010 23:00:00 +0100 3735643 Lilly to Acquire Alnara Pharmaceuticals http://www.medworm.com/index.php?rid=3731964&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1295%2F30%2F Eli Lilly and Company (NYSE: LLY) and Alnara Pharmaceuticals, Inc. have signed a definitive merger agreement whereby Lilly will acquire Alnara, a privately held biotechnology company developing protein therapeutics for the treatment of metabolic diseases. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3731964 Wed, 07 Jul 2010 23:00:00 +0100 3731964 Nycomed's Daxas® (roflumilast) receives marketing authorisation in the European Union http://www.medworm.com/index.php?rid=3728377&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1294%2F32%2F Nycomed announced that the European Commission has granted marketing authorisation for Daxas® (roflumilast) in the European Union. Daxas® is a proprietary selective phosphodiesterase 4 (PDE4) enzyme inhibitor that has been developed by Nycomed for the treatment of COPD, a progressive, life-threatening lung disease. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3728377 Tue, 06 Jul 2010 23:00:00 +0100 3728377 6th Annual Project & Portfolio Management in the Pharmaceutical Industry http://www.medworm.com/index.php?rid=3728378&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1293%2F28%2F 28 - 29 September 2010, Milan, Italy. After 5 successful annuals and the industry feedback, Jacob Fleming Conferences is bringing a well-balanced program full of real life case studies on major achievements in Project & Portfolio Management Approaches established across leading Pharma companies. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3728378 Mon, 05 Jul 2010 23:00:00 +0100 3728378 AstraZeneca and MRC Technology Form Strategic Alliance in Discovery Research http://www.medworm.com/index.php?rid=3725854&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1292%2F30%2F AstraZeneca and MRC Technology, the commercialisation company for the UK's Medical Research Council, announced a new strategic collaboration to share access to their collections of compounds to aid the search for potential new treatments for serious diseases. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3725854 Mon, 05 Jul 2010 23:00:00 +0100 3725854 Daiichi Sankyo and Ranbaxy to Integrate New Drug Research and Development System http://www.medworm.com/index.php?rid=3724204&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1290%2F30%2F Daiichi Sankyo Company Limited ("Daiichi Sankyo") and Ranbaxy Laboratories Limited ("Ranbaxy") announced that Ranbaxy's New Drug Discovery Research ("NDDR") has been transferred to Daiichi Sankyo India Pharma Private Limited as part of the strategy to strengthen the global Research and Development (R&D) structure of the Daiichi Sankyo Group. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3724204 Sun, 04 Jul 2010 23:00:00 +0100 3724204 Expanding access to medicines for people living in the world's poorest countries http://www.medworm.com/index.php?rid=3724203&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1291%2F30%2F As part of its commitment to further transform the company's approach to diseases that disproportionately affect the world's poorest people, GlaxoSmithKline (GSK) is creating a new operating unit dedicated to the Least Developed Countries (LDCs*). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3724203 Sun, 04 Jul 2010 23:00:00 +0100 3724203 Roche and IBM Collaborate to Develop Nanopore-Based DNA Sequencing Technology http://www.medworm.com/index.php?rid=3716750&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1287%2F27%2F Roche (SIX: RO, ROG; OTCQX: RHHBY) and IBM (NYSE: IBM) announced an agreement to develop a nanopore-based technology that will directly read and sequence human DNA quickly and efficiently. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3716750 Thu, 01 Jul 2010 23:00:00 +0100 3716750 Phase III study shows Novartis drug Afinitor® more than doubles time without tumor growth http://www.medworm.com/index.php?rid=3716749&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1288%2F29%2F Novartis announced that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3716749 Thu, 01 Jul 2010 23:00:00 +0100 3716749 Sanofi-aventis and JDRF Form Partnership to Improve Therapies http://www.medworm.com/index.php?rid=3716748&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1289%2F30%2F Sanofi-aventis (EURONEXT: SAN and NYSE: SNY ) and the Juvenile Diabetes Research Foundation (JDRF) announced a unique partnership to develop therapeutic treatments for people with type 1 diabetes at different stages of the disease - both those living with the disease and the newly diagnosed - as well as preventing diabetes in those at risk. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3716748 Thu, 01 Jul 2010 23:00:00 +0100 3716748 Manhattan Research Releases Latest Study Focused on How Nurses Use the Internet and Technology http://www.medworm.com/index.php?rid=3712493&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1285%2F27%2F Pharmaceutical and healthcare market research company Manhattan Research releases Taking the Pulse® Nurses v10.0, the latest iteration of its study focused on how nurses use digital resources, handheld devices, and other technologies in the professional setting. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3712493 Wed, 30 Jun 2010 23:00:00 +0100 3712493 Shire Purchases Strategic Site in Massachusetts http://www.medworm.com/index.php?rid=3712492&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1286%2F31%2F Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced its purchase of the Lexington Technology Park campus in Lexington, Massachusetts. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3712492 Wed, 30 Jun 2010 23:00:00 +0100 3712492 Single Treatment with ELONVA® Produced Live Birth Rates Comparable to Daily rFSH Injections http://www.medworm.com/index.php?rid=3708868&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1284%2F29%2F MSD announced findings from a follow-up study to the pivotal Engage Phase III trial. Treatment with a single corifollitropin alfa injection had comparable live birth rates with daily recombinant follicle stimulating hormone (rFSH) injections for the first week of stimulation. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3708868 Tue, 29 Jun 2010 23:00:00 +0100 3708868 6th Annual Pharma Marketing & Branding Excellence http://www.medworm.com/index.php?rid=3708869&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1283%2F28%2F 23 - 24 September 2010, Milan, Italy. Recently, behaviors of pharmaceutical marketing landscape, which includes health care providers, patients, and consumers are changing. Pharma companies are now favoring marketing through new media technologies like mobile-Web integration and online interactivity. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3708869 Mon, 28 Jun 2010 23:00:00 +0100 3708869 AstraZeneca and MMV Join Efforts in the Fight Against Malaria http://www.medworm.com/index.php?rid=3705166&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1282%2F30%2F AstraZeneca and Medicines for Malaria Venture (MMV) announced a collaborative agreement designed to identify novel candidate drugs for the treatment of malaria. The agreement will initially allow MMV access to AstraZeneca's extensive compound library. MMV will seek to identify promising compounds with the potential to treat malaria, including drug resistant strains of the disease. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3705166 Mon, 28 Jun 2010 23:00:00 +0100 3705166 ONGLYZA™ (saxagliptin) with Metformin as Initial Combination Therapy http://www.medworm.com/index.php?rid=3702583&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1280%2F29%2F Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) announced results up to 76-weeks from a Phase 3 study of ONGLYZA™ (saxagliptin) as initial combination therapy with metformin, which produced long-term glycemic improvement [as measured by glycosylated hemoglobin level (HbA1c)] in treatment-naïve adults with type 2 diabetes mellitus inadequately controlled on diet and exercise compared to treatment with an investigational 10 mg dose of saxagliptin or metformin alone. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3702583 Sun, 27 Jun 2010 23:00:00 +0100 3702583 Victoza® (liraglutide) provided superior and sustained blood sugar control and weight reduction http://www.medworm.com/index.php?rid=3702582&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1281%2F29%2F Late-breaking Novo Nordisk extension data presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily Victoza® in combination with metformin produced sustained and significantly greater reductions in A1c, body weight and fasting plasma glucose (FPG) than Januvia® plus metformin at 52 weeks. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3702582 Sun, 27 Jun 2010 23:00:00 +0100 3702582 Pfizer Suspends Tanezumab Osteoarthritis Clinical Trial Program http://www.medworm.com/index.php?rid=3693545&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1279%2F29%2F Pfizer Inc. (NYSE: PFE) announced the suspension of the osteoarthritis clinical program for the investigational compound tanezumab following a request by the U.S. Food and Drug Administration (FDA). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3693545 Thu, 24 Jun 2010 23:00:00 +0100 3693545 Pharmaceutical Companies to Tap Opportunities in Emerging Markets http://www.medworm.com/index.php?rid=3693546&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1278%2F27%2F The increased cost of drug development has impelled pharmaceutical companies to seek better opportunities in emerging markets to successfully expand and sell their products. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3693546 Wed, 23 Jun 2010 23:00:00 +0100 3693546 AstraZeneca and Targacept Initiate Phase 3 Clinical Development of TC-5214 http://www.medworm.com/index.php?rid=3689363&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1277%2F29%2F AstraZeneca and Targacept, Inc., announced the enrolment of the first patient in the Phase 3 clinical development program for TC-5214, a nicotinic channel blocker. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3689363 Wed, 23 Jun 2010 23:00:00 +0100 3689363 New SIMPONI™ (Golimumab) Data Shows Sustained Efficacy in the Treatment of Rheumatoid Arthritis http://www.medworm.com/index.php?rid=3685687&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1275%2F29%2F Findings from an open-label, uncontrolled long-term extension of a Phase 3 registration trial demonstrated efficacy of SIMPONI in patients with moderately to severely active rheumatoid arthritis despite methotrexate therapy at two years. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3685687 Tue, 22 Jun 2010 23:00:00 +0100 3685687 34 Teachers and Schools Across North America Receive $10,000 Amgen Award http://www.medworm.com/index.php?rid=3685686&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1276%2F30%2F Amgen (Nasdaq: AMGN) announced the 34 science teachers in the United States (U.S.), Canada and Puerto Rico who are this year's recipients of the 18th annual Amgen Award for Science Teaching Excellence. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3685686 Tue, 22 Jun 2010 23:00:00 +0100 3685686 FDA approves Tasigna® for newly diagnosed chronic myeloid leukemia patients http://www.medworm.com/index.php?rid=3682157&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1274%2F32%2F Following a priority review, the US Food and Drug Administration (FDA) has approved Tasigna® (nilotinib) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3682157 Mon, 21 Jun 2010 23:00:00 +0100 3682157 RoACTEMRA: New hope for children with systemic Juvenile Idiopathic Arthritis http://www.medworm.com/index.php?rid=3679426&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1272%2F29%2F Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that new data being presented at the European League Against Rheumatism (EULAR) congress demonstrates that RoACTEMRA (known as ACTEMRA outside Europe) is highly effective in improving the signs and symptoms of systemic Juvenile Idiopathic Arthritis (sJIA), a severe childhood arthritis, where there are no currently licensed treatments. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3679426 Sun, 20 Jun 2010 23:00:00 +0100 3679426 Surplus PC Power Yields Faster Cancer Research http://www.medworm.com/index.php?rid=3679425&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1273%2F27%2F Scientists have devised a way to automate and accelerate a manual, complex process that enables researchers to more easily discover the structure of cancer-related proteins, and, eventually, formulate cancer cures. This new, automated approach may also help the exploration of other diseases and food-related research. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3679425 Sun, 20 Jun 2010 23:00:00 +0100 3679425 Global E-Health Forum to Present Strategies, Solutions and Services http://www.medworm.com/index.php?rid=3669339&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1270%2F28%2F 25 - 26 October 2010, Hamburg, Germany. Healthcare systems all over the world are facing very similar challenges: demographic shifts, the impact of globalization and an increased burden of chronic diseases and expensive treatments, to mention some of the most important ones. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3669339 Thu, 17 Jun 2010 23:00:00 +0100 3669339 Bayer Schering Pharma and OncoMed Pharmaceuticals Enter Strategic Alliance http://www.medworm.com/index.php?rid=3669338&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1271%2F30%2F Bayer Schering Pharma AG, Germany, and OncoMed Pharmaceuticals, Inc., announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3669338 Thu, 17 Jun 2010 23:00:00 +0100 3669338 The IT @ Networking Awards 2010 - Open Competition for Healthcare IT Solutions http://www.medworm.com/index.php?rid=3669341&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1268%2F27%2F The IT @ Networking Awards 2010 (IT @ 2010) is an open competition for fully implemented, operable healthcare IT solutions. The goal is to raise awareness of some of the world's finest and most innovative local, regional and national healthcare IT projects. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3669341 Wed, 16 Jun 2010 23:00:00 +0100 3669341 Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix http://www.medworm.com/index.php?rid=3669340&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1269%2F30%2F Abbott (NYSE: ABT) and Neurocrine Biosciences, Inc. have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3669340 Wed, 16 Jun 2010 23:00:00 +0100 3669340 FDA to Communicate Safety Monitoring Activities to Consumers and Health Care Professionals http://www.medworm.com/index.php?rid=3664537&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1267%2F27%2F The U.S. Food and Drug Administration unveiled a new source of information for patients and health care professionals on the safety of recently approved drugs and biologics. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3664537 Tue, 15 Jun 2010 23:00:00 +0100 3664537 Bristol-Myers Squibb Signs Agreements with ICON and PAREXEL http://www.medworm.com/index.php?rid=3661352&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1264%2F30%2F Bristol-Myers Squibb Company (NYSE: BMY) has signed agreements with ICON and PAREXEL, two leading providers of clinical development services to the biopharmaceutical industry, for joint strategic, operational and capability support of the company's clinical development program. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3661352 Mon, 14 Jun 2010 23:00:00 +0100 3661352 Genzyme’s Alemtuzumab for Treatment of Multiple Sclerosis Granted Fast Track Status by FDA http://www.medworm.com/index.php?rid=3661351&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1265%2F32%2F Genzyme Corporation (Nasdaq: GENZ) announced that its alemtuzumab for multiple sclerosis development program has been granted Fast Track status by the U.S. Food and Drug Administration (FDA). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3661351 Mon, 14 Jun 2010 23:00:00 +0100 3661351 Boehringer Ingelheim affirms safety of telmisartan with an analysis of 50,000 patients http://www.medworm.com/index.php?rid=3661350&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1266%2F32%2F Telmisartan, an angiotensin receptor blocker, is one of the best researched drugs worldwide. It has been studied in clinical trials in more than 50,000 patients. Its positive safety profile has been confirmed also in a market exposure of 34.5 million patient years. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3661350 Mon, 14 Jun 2010 23:00:00 +0100 3661350 FDA advisory committee recommends approval of Novartis investigational treatment FTY720 http://www.medworm.com/index.php?rid=3657966&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1262%2F32%2F An advisory committee of the US Food and Drug Administration (FDA) recommended approval of FTY720 (fingolimod) for the treatment of patients with relapsing multiple sclerosis, the most common form of the disease. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3657966 Sun, 13 Jun 2010 23:00:00 +0100 3657966 Trial of Nexavar® in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint http://www.medworm.com/index.php?rid=3657965&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1263%2F29%2F Bayer HealthCare and Onyx Pharmaceuticals today announced that the final analysis of the Phase III NExUS (NSCLC research Experience Utilizing Sorafenib) trial evaluating Nexavar® (sorafenib) tablets in patients with advanced non-squamous, non-small cell lung cancer (NSCLC) showed that the trial did not meet its primary endpoint of improving overall survival in the first-line setting. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3657965 Sun, 13 Jun 2010 23:00:00 +0100 3657965 AVERROES Study Closes Early Due to Clear Evidence of Efficacy http://www.medworm.com/index.php?rid=3650869&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1260%2F29%2F Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3650869 Thu, 10 Jun 2010 23:00:00 +0100 3650869 GSK drives Latin America growth strategy with acquisition of Laboratorios Phoenix http://www.medworm.com/index.php?rid=3650868&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1261%2F31%2F GlaxoSmithKline plc (GSK) has acquired Laboratorios Phoenix S.A.C.yF ('Phoenix'), a leading Argentine pharmaceutical business, for a cash consideration of approximately $253 million. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3650868 Thu, 10 Jun 2010 23:00:00 +0100 3650868 Americans Are Not Taking Action to Protect Themselves Against Muscle Loss http://www.medworm.com/index.php?rid=3646776&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1258%2F27%2F Nearly nine in 10 people think feeling weaker is one of the worst parts about aging, according to a recent survey commissioned by Abbott and developed in conjunction with the AGS Foundation for Health in Aging, a nonprofit dedicated to the health and well-being of older adults, which provided expert, independent review. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3646776 Wed, 09 Jun 2010 23:00:00 +0100 3646776 Ranbaxy Launches Antiplatelet Agent Prasugrel in India http://www.medworm.com/index.php?rid=3646775&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1259%2F32%2F Daiichi Sankyo Company Limited ("Daiichi Sankyo") and Ranbaxy Laboratories Limited ("Ranbaxy") announced today that Ranbaxy has launched a generic version of prasugrel in India. The product, called Prasita, is an antiplatelet agent for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3646775 Wed, 09 Jun 2010 23:00:00 +0100 3646775 Sanofi Pasteur Partners with Vivalis for the Discovery of Human Monoclonal Antibodies http://www.medworm.com/index.php?rid=3643109&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1257%2F30%2F Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced the signature with Vivalis (NYSE and Euronext: VLS) of a commercial license and collaboration agreement for the discovery and development of fully human monoclonal antibodies against several infectious diseases. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3643109 Tue, 08 Jun 2010 23:00:00 +0100 3643109 British Medical Journal: WHO must act now to restore its credibility, and Europe should legislate http://www.medworm.com/index.php?rid=3639344&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1255%2F27%2F Council of Europe condemns "unjustified scare" over swine flu Adrian O'Dowd The Council of Europe has heavily criticised the World Health Organization, national governments, and EU agencies for their handling of the swine flu pandemic. The parliamentary assembly of the council - the international organisation that protects human rights and the rule of law in Europe - published a draft of a report that reviewed how the H1N1 pandemic was handled. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3639344 Mon, 07 Jun 2010 23:00:00 +0100 3639344 Merck Resubmits U.S. Application for Cladribine Tablets http://www.medworm.com/index.php?rid=3639343&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1256%2F32%2F Merck KGaA announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Cladribine Tablets as a therapy for reducing relapses in people with relapsing forms of multiple sclerosis (MS). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3639343 Mon, 07 Jun 2010 23:00:00 +0100 3639343 Phase 3 Study Showed MACUGEN® Improved Vision Over Standard of Care http://www.medworm.com/index.php?rid=3634670&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1253%2F29%2F Results from a Phase 3 study demonstrate MACUGEN® (pegaptanib sodium) significantly improved vision in patients with diabetic macular edema (DME), a complication of diabetes that is a leading cause of blindness in people of working age.(1) (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3634670 Sun, 06 Jun 2010 23:00:00 +0100 3634670 Phase III study showed Avastin-based regimen helped women with advanced ovarian cancer http://www.medworm.com/index.php?rid=3634669&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1254%2F29%2F Roche (SIX: RO, ROG; OTCQX: RHHBY) announced results from a Phase III study of Avastin (bevacizumab) that showed women with previously untreated advanced ovarian cancer who received Avastin in combination with chemotherapy, followed by the continuation of Avastin alone, had a 39 percent improvement in the likelihood of living longer without the disease worsening compared to chemotherapy alone. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3634669 Sun, 06 Jun 2010 23:00:00 +0100 3634669 Philips and RXi Pharmaceuticals entered into a joint research agreement http://www.medworm.com/index.php?rid=3627807&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1251%2F27%2F Royal Philips Electronics (NYSE: PHG, AEX: PHI) and RXi Pharmaceuticals Corporation (Nasdaq: RXII), a US-based biopharmaceutical company, have entered into a joint research agreement to explore the benefits of combining proprietary technologies from both companies for the targeted delivery of experimental therapeutics based on RNA interference (RNAi). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3627807 Thu, 03 Jun 2010 23:00:00 +0100 3627807 Merck Announces Launch of Pioneering Collaborative Cancer Trials Network http://www.medworm.com/index.php?rid=3627806&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1252%2F29%2F Merck announced the launch of the Merck Oncology Collaborative Trials Network, a pioneering clinical trial network focusing on the development of Merck drug and vaccine candidates being investigated for the treatment and prevention of cancer. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3627806 Thu, 03 Jun 2010 23:00:00 +0100 3627806 FDA Approves Amgen's Prolia(TM) (Denosumab) for Treatment of Postmenopausal Women with Osteoporosis http://www.medworm.com/index.php?rid=3623679&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1250%2F32%2F Amgen Inc. (Nasdaq: AMGN) announced that the U.S. Food and Drug Administration (FDA) has approved Prolia(TM) (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3623679 Wed, 02 Jun 2010 23:00:00 +0100 3623679 Victoza® to be launched in Japan in June http://www.medworm.com/index.php?rid=3619931&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1249%2F32%2F Novo Nordisk today announced that it has received approval of the price of Victoza®, a once-daily human GLP-1 analogue for the treatment of type 2 diabetes, from Japan's Central Social Insurance Medical Council (Chuikyo), the advisory committee to the Minister of Health, Labour and Welfare. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3619931 Tue, 01 Jun 2010 23:00:00 +0100 3619931 AstraZeneca Receives FDA Complete Response Letter for AXANUM New Drug Application http://www.medworm.com/index.php?rid=3619932&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1248%2F32%2F AstraZeneca has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the new drug application for AXANUM (aspirin/esomeprazole magnesium) tablets. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3619932 Mon, 31 May 2010 23:00:00 +0100 3619932 Sanofi-aventis and Generics Leader Nichi-Iko to Establish New Joint Venture for Generics in Japan http://www.medworm.com/index.php?rid=3619933&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1247%2F30%2F Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Nichi-Iko Pharmaceutical Co., Ltd. (Nichi-Iko) (Osaka Stock Exchange and Nagoya Stock Exchange: NIK) have signed an agreement to establish a new joint venture, called sanofi-aventis Nichi-Iko K.K., in order to develop a generic business in Japan. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3619933 Sun, 30 May 2010 23:00:00 +0100 3619933 Novartis announces extension of US regulatory priority review period for FTY720 http://www.medworm.com/index.php?rid=3605814&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1246%2F32%2F Novartis announced that the US Food and Drug Administration (FDA) has extended by three months, to September 2010, its review period for the regulatory approval of FTY720 (fingolimod). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3605814 Thu, 27 May 2010 23:00:00 +0100 3605814 FDA Announces Collaboration with Drugs.com http://www.medworm.com/index.php?rid=3601865&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1243%2F27%2F The U.S. Food and Drug Administration announced today that it will collaborate with the Web site Drugs.com to expand access to the FDA's consumer health information. Drugs.com seeks to provide patients with information to better manage their own health care and to assist in the reduction of medication errors. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3601865 Wed, 26 May 2010 23:00:00 +0100 3601865 Keynote on U.S. Health Reform at Global E-Health Forum - Hamburg 2010 http://www.medworm.com/index.php?rid=3601864&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1244%2F28%2F 25-26 October 2010, Hamburg, Germany. Harry Reynolds, Chair of the National Committee on Vital and Health Statistics (NCVHS) and Chair of Council for Affordable Quality Healthcare (CAQH) CORE Initiative, will deliver the keynote speech at the Global E-Health Forum. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3601864 Wed, 26 May 2010 23:00:00 +0100 3601864 FDA: Rare Cases of Liver Injury Reported with Use of Xenical, Alli http://www.medworm.com/index.php?rid=3601863&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1245%2F32%2F The U.S. Food and Drug Administration advised consumers and health care professionals about potential rare occurrences of severe liver injury in patients taking the weight-loss medication orlistat, marketed as Xenical and Alli. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3601863 Wed, 26 May 2010 23:00:00 +0100 3601863 Genzyme Receives FDA Approval for Lumizyme for Pompe Disease http://www.medworm.com/index.php?rid=3597807&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1240%2F32%2F Genzyme Corporation (Nasdaq: GENZ) announced that the FDA has granted U.S. marketing approval for Lumizyme™ (alglucosidase alfa), produced at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3597807 Tue, 25 May 2010 23:00:00 +0100 3597807 Transinsight and antibodies-online Develop Software for Semantic Gene and Protein Identification http://www.medworm.com/index.php?rid=3597806&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1241%2F27%2F Since July 2009 Transinsight GmbH and antibodies-online GmbH partner together with TU Dresden and RESprotect GmbH to develop and deploy new semantic search technologies for the Life-Science industry. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3597806 Tue, 25 May 2010 23:00:00 +0100 3597806 Results of the clinical study CALYPSO Published in The Journal of Clinical Oncology http://www.medworm.com/index.php?rid=3597805&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1242%2F29%2F Results of the clinical study CALYPSO, published online by The Journal of Clinical Oncology, show that patients in this study with platinum-sensitive relapsed ovarian cancer experienced longer progression-free survival than patients taking the current standard of care. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3597805 Tue, 25 May 2010 23:00:00 +0100 3597805 European Medicines Agency maintains position on the continued use of Rotarix™ http://www.medworm.com/index.php?rid=3594096&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1239%2F32%2F GlaxoSmithKline (GSK) confirmed that following a meeting of the Committee for Medicinal Products for Human Use (CHMP), the European Medicines Agency (EMA) has maintained its position that there is no evidence that the presence of porcine circovirus (PCV) in Rotarix™ presents a risk to public health and that there is no need to restrict its use in the European Union. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3594096 Mon, 24 May 2010 23:00:00 +0100 3594096 Ranibizumab significantly more effective than standard of care in treating vision loss due to DME http://www.medworm.com/index.php?rid=3594097&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1238%2F29%2F First results of the RESTORE Phase III study show that ranibizumab is significantly more effective than laser treatment, the current standard of care, at treating visual impairment due to diabetic macular edema (DME), a serious complication of diabetes[1]. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3594097 Sun, 23 May 2010 23:00:00 +0100 3594097 The PHARM Connect Congress 2011 http://www.medworm.com/index.php?rid=3583790&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1235%2F28%2F 9-10 February 2011, Budapest, Hungary. The PHARM Connect Congress 2011, an event organised by The Events Group, offers the perfect setting for solution providers to present their products and services directly to key decision makers of target client population throughout Central & Eastern Europe. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3583790 Thu, 20 May 2010 23:00:00 +0100 3583790 New Twist on Potential Malaria Drug Target Acts by Trapping Parasites in Cells http://www.medworm.com/index.php?rid=3583789&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1236%2F27%2F Harvard School of Public Health (HSPH) researchers and colleagues seeking to block invasion of healthy red blood cells by malaria parasites have instead succeeded in locking the parasites within infected blood cells, potentially containing the disease. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3583789 Thu, 20 May 2010 23:00:00 +0100 3583789 Abbott to Become No. 1 Pharmaceutical Company in India http://www.medworm.com/index.php?rid=3583788&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1237%2F31%2F Abbott (NYSE: ABT) announced a definitive agreement with Piramal Healthcare Limited to acquire full ownership of Piramal's Healthcare Solutions business (Domestic Formulations), a leader in the Indian branded generics market, for an up-front payment of $2.12 billion, plus $400 million annually for the next four years, giving Abbott the No. 1 position in the Indian pharmaceutical market. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3583788 Thu, 20 May 2010 23:00:00 +0100 3583788 Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. http://www.medworm.com/index.php?rid=3579790&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1233%2F31%2F Astellas Pharma Inc. (TSE: 4503), a global pharmaceutical company, and OSI Pharmaceuticals, Inc. (Nasdaq: OSIP), a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing medical needs in oncology, diabetes and obesity, have entered into a definitive merger agreement under which Astellas will acquire OSI. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3579790 Wed, 19 May 2010 23:00:00 +0100 3579790 Pfizer Global Manufacturing Announces Plans to Reconfigure its Global Plant Network http://www.medworm.com/index.php?rid=3579789&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1234%2F30%2F Pfizer Global Manufacturing announced plans to reconfigure its worldwide plant network to create a fully aligned manufacturing and supply organization from the combined networks of Pfizer and Wyeth. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3579789 Wed, 19 May 2010 23:00:00 +0100 3579789 Sanofi-aventis Announces the Creation of the "Sanofi Espoir" Corporate Foundation http://www.medworm.com/index.php?rid=3579791&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1231%2F30%2F Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced the creation of the Sanofi Espoir Corporate Foundation, dedicated to implementing health and solidarity programs worldwide. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3579791 Tue, 18 May 2010 23:00:00 +0100 3579791 Forest Laboratories and Nycomed Receive Complete Response Letter for Roflumilast http://www.medworm.com/index.php?rid=3575562&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1229%2F32%2F Forest Laboratories, Inc. (NYSE: FRX) and Nycomed announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for roflumilast. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3575562 Tue, 18 May 2010 23:00:00 +0100 3575562 Can a single, cheap pill combat cardiovascular disease? http://www.medworm.com/index.php?rid=3575561&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1230%2F27%2F Volunteers are being recruited in Ireland, the Netherlands and the UK to participate in a two-year trial of a single 'polypill' designed to prevent heart attack and stroke. The trials are financed in part by the UMPIRE (Use of a multidrug pill in reducing cardiovascular events) project, which has received EUR 3 million under the Health Theme of the Seventh Framework Programme (FP7). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3575561 Tue, 18 May 2010 23:00:00 +0100 3575561 Sanofi-aventis Announces the Creation of the "Sanofi Espoir" Corporate Foundation http://www.medworm.com/index.php?rid=3575560&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1231%2F27%2F Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced the creation of the Sanofi Espoir Corporate Foundation, dedicated to implementing health and solidarity programs worldwide. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3575560 Tue, 18 May 2010 23:00:00 +0100 3575560 Pharma CRM Goes on the iPad and iPhone http://www.medworm.com/index.php?rid=3575559&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1232%2F27%2F Media-Soft, CRM solutions provider for pharmaceutical companies, announced the launch of the native and offline iPhone adn iPad Pharma CRM application with advanced and unique features that increase the Sales Force effectiveness in pharma organizations. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3575559 Tue, 18 May 2010 23:00:00 +0100 3575559 Positive pivotal results on escitalopram in Japan http://www.medworm.com/index.php?rid=3572059&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1227%2F29%2F H. Lundbeck A/S (Lundbeck) announced that the results from the pivotal study with escitalopram in Japan have been received. The results are positive and according to expectations. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3572059 Mon, 17 May 2010 23:00:00 +0100 3572059 Bayer Schering Pharma Enhances U.S. Research Strategy with New Innovation Center http://www.medworm.com/index.php?rid=3572058&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1228%2F30%2F Bayer Schering Pharma AG, Germany, will establish a U.S. Innovation Center in San Francisco, Calif. with the goal to expand its global research network and build its specialty pharmaceutical pipeline. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3572058 Mon, 17 May 2010 23:00:00 +0100 3572058 Bayer receives approval for its new oral contraceptive in the U.S. http://www.medworm.com/index.php?rid=3569126&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1225%2F32%2F Bayer Schering Pharma AG, Germany, has received approval from The U.S. entity of Food and Drug Administration (FDA) for its new Natazia® (estradiol valerate/ dienogest) pill for the prevention of pregnancy. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3569126 Sun, 16 May 2010 23:00:00 +0100 3569126 Covex S.A. creates 2000 jobs with the onset of a new agroindustrial project in Latin America http://www.medworm.com/index.php?rid=3569125&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1226%2F30%2F Covex S.A., leader in the manufacture of products aimed at improving cerebral functions, successfully reaches the first stage of its introduction in Latin America, as it begins to harvest medicinal plants on an industrial scale, for the onset of its new agroindustrial expansion. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3569125 Sun, 16 May 2010 23:00:00 +0100 3569125 RA.com Features Interactive Resource to Help People Living with Rheumatoid Arthritis http://www.medworm.com/index.php?rid=3562409&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1223%2F27%2F As any do-it-yourselfer knows, a good home improvement project has both style and substance, adding functionality with aesthetic appeal. For people with rheumatoid arthritis (RA) who may face difficulties around the house, adaptable options around the home are particularly important. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3562409 Thu, 13 May 2010 23:00:00 +0100 3562409 'Bad Ad Program' to Help Health Care Providers Detect, Report Misleading Drug Ads http://www.medworm.com/index.php?rid=3562408&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1224%2F27%2F The U.S. Food and Drug Administration launched a program designed to educate health care providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3562408 Thu, 13 May 2010 23:00:00 +0100 3562408 GSK extends presence in Asia with new strategic alliance in South Korea http://www.medworm.com/index.php?rid=3558630&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1221%2F31%2F GlaxoSmithKline (GSK) entered into a strategic alliance with Dong-A Pharmaceuticals Co., Ltd. (Dong-A), the number one pharmaceutical and OTC Company in South Korea. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3558630 Wed, 12 May 2010 23:00:00 +0100 3558630 New study results on Dulcolax® confirm efficacy and safety http://www.medworm.com/index.php?rid=3558629&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1222%2F29%2F In a clinical study Boehringer Ingelheim recently conducted, Dulcolax® tablets with the active ingredient bisacodyl clearly demonstrated efficacy by increasing the frequency and regularity of bowel movements. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3558629 Wed, 12 May 2010 23:00:00 +0100 3558629 Abbott licenses 24 Zydus pharmaceutical products for 15 high-growth emerging markets http://www.medworm.com/index.php?rid=3554477&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1219%2F30%2F Further strengthening its global competitive position, Abbott (NYSE: ABT) announced a licensing and supply agreement with Zydus Cadila of India for a portfolio of pharmaceutical products that Abbott will commercialize in 15 emerging markets, enabling the company to further accelerate its emerging markets growth. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3554477 Tue, 11 May 2010 23:00:00 +0100 3554477 Merck Positioned to Drive Growth Through Innovative Portfolio, Pipeline and Strategy http://www.medworm.com/index.php?rid=3554476&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1220%2F30%2F Merck & Co., Inc. (NYSE: MRK) hosted its first R&D and Business Briefing since completion of the Merck and Schering-Plough merger and outlined the company's strategy to drive global business growth. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3554476 Tue, 11 May 2010 23:00:00 +0100 3554476 GSK Statement on FDA Advisory Committee meeting on Rotavirus vaccines http://www.medworm.com/index.php?rid=3550927&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1217%2F32%2F GlaxoSmithKline (NYSE: GSK) participated in a U.S. Food and Drug Administration (FDA) advisory committee meeting convened to discuss recent findings of porcine circovirus (PCV) in rotavirus vaccines. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3550927 Mon, 10 May 2010 23:00:00 +0100 3550927 How Unbranded Websites Can Extend Brand Reach throughout the Patient Life Cycle? http://www.medworm.com/index.php?rid=3550926&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1218%2F27%2F Consumer reliance on condition-focused content during the disease research process, growing emphasis on customer care throughout the treatment continuum, and uncertainty around the DTC regulatory environment is prompting increased interest in unbranded online initiatives. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3550926 Mon, 10 May 2010 23:00:00 +0100 3550926 Bayer Schering Pharma Initiates Phase III Trial of Regorafenib http://www.medworm.com/index.php?rid=3548055&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1215%2F29%2F Bayer Schering Pharma AG, Germany, has started to enroll patients in an international Phase III trial to evaluate its investigational compound regorafenib (BAY 73-4506) for the treatment of patients with metastatic colorectal cancer (CRC) who have progressed after standard therapies. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3548055 Sun, 09 May 2010 23:00:00 +0100 3548055 EDUCARE (EDUcation for Cancer in African REgions) Project http://www.medworm.com/index.php?rid=3548054&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1216%2F27%2F Roche announced the launch of the EDUCARE (EDUcation for Cancer in African REgions) project, which, in concert with IAEA (International Atomic Energy Agency), will provide support to help combat the growing cancer epidemic in sub-Saharan Africa. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3548054 Sun, 09 May 2010 23:00:00 +0100 3548054 BioConference Live for the Life Science and Biotech Community http://www.medworm.com/index.php?rid=3540758&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1213%2F28%2F 2-3 June 2010. BioConference Live is an information break through and the first of its kind online-only conference for the life sciences and laboratory science community. This FREE event will feature live video keynote presentations from life science thought leaders where attendees can have their question answered by presenters in real time. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3540758 Thu, 06 May 2010 23:00:00 +0100 3540758 Lundbeck delivers strong growth http://www.medworm.com/index.php?rid=3540757&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1214%2F31%2F H. Lundbeck A/S (Lundbeck) reports first quarter revenue of DKK 3,849 million growing 15% in constant exchange rates compared to the first quarter results of 2009. Profit from operations was DKK 1,254 million, an increase of 32% compared to the same period last year. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3540757 Thu, 06 May 2010 23:00:00 +0100 3540757 Bayer Schering Pharma and EndoCeutics Enter into a Global Agreement http://www.medworm.com/index.php?rid=3536398&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1211%2F30%2F Bayer Schering Pharma AG, Germany, has signed a global exclusive cooperation agreement with the Canadian company EndoCeutics, Inc. for the development and commercialization of Vaginorm, an intra-vaginal application of dehydroepiandrosterone (DHEA). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3536398 Wed, 05 May 2010 23:00:00 +0100 3536398 Boehringer Ingelheim and Micromet announce global collaboration for multiple myeloma BiTE antibody http://www.medworm.com/index.php?rid=3536397&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1212%2F30%2F Boehringer Ingelheim and Micromet, Inc. (Nasdaq: MITI) have entered into a collaboration agreement for the research, development and commercialization of a new BiTE antibody for the treatment of multiple myeloma. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3536397 Wed, 05 May 2010 23:00:00 +0100 3536397 Merck Announces First-Quarter 2010 Financial Results http://www.medworm.com/index.php?rid=3532394&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1209%2F31%2F Merck & Co., Inc. (NYSE: MRK) announced financial results for the first quarter of 2010. Worldwide sales for the first quarter of 2010 were $11.4 billion. Net income for the first quarter was $299 million. Foreign exchange for the quarter favorably affected global sales performance by 4 percent. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3532394 Tue, 04 May 2010 23:00:00 +0100 3532394 Open Forum 4 - Key Issues in TB Drug Development http://www.medworm.com/index.php?rid=3532393&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1210%2F28%2F 18-19 August 2010, Hilton Hotel, Addis Ababa, Ethiopia. This two-day Open Forum will be the fourth in a series of meetings aimed to raise and address key issues in TB drug development, with a special focus on regulatory affairs. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3532393 Tue, 04 May 2010 23:00:00 +0100 3532393 FDA approved VIMOVO for arthritis patients at risk of developing NSAID-associated gastric ulcers http://www.medworm.com/index.php?rid=3528492&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1208%2F32%2F AstraZeneca and POZEN Inc. announced the US Food and Drug Administration (FDA) has approved VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3528492 Mon, 03 May 2010 23:00:00 +0100 3528492 Bristol-Myers Squibb Reports Strong Sales, Earnings Performance in First Quarter http://www.medworm.com/index.php?rid=3525395&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1206%2F31%2F Bristol-Myers Squibb Company (NYSE: BMY) reported strong sales and earnings growth for the first quarter of 2010. "Double-digit growth for both sales and earnings per share marks a very positive start to the year for our company," said Lamberto Andreotti, CEO-designate, Bristol-Myers Squibb. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3525395 Sun, 02 May 2010 23:00:00 +0100 3525395 Nycomed and Merck & Co., Inc., announce commercialization agreements for Daxas® http://www.medworm.com/index.php?rid=3525394&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1207%2F32%2F Nycomed and Merck & Co., Inc. have entered into a co-promotion agreement for Canada and certain European countries for the commercialization of Daxas® (roflumilast), an investigational once-daily tablet for patients with chronic obstructive pulmonary disease (COPD). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3525394 Sun, 02 May 2010 23:00:00 +0100 3525394 Bayer achieves strong gains in sales and earnings http://www.medworm.com/index.php?rid=3517640&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1203%2F31%2F Sales of the Bayer Group rose by 5.3 percent in the first quarter to EUR 8,316 million (Q1 2009: EUR 7,895 million). Adjusted for currency and portfolio effects, business grew by 6.2 percent. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3517640 Thu, 29 Apr 2010 23:00:00 +0100 3517640 AstraZeneca's first quarter results reflect continued strong market performance http://www.medworm.com/index.php?rid=3517639&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1204%2F31%2F AstraZeneca's revenue in the first quarter increased by 7 percent at CER, but was up 11 percent on an actual basis as a result of the positive impact of exchange rate movements. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3517639 Thu, 29 Apr 2010 23:00:00 +0100 3517639 The IT @ Networking Awards 2010 http://www.medworm.com/index.php?rid=3517638&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1205%2F27%2F The goal of the IT @ Networking Awards 2010 (IT @ 2010), is to honour and promote outstanding healthcare IT solutions. The core aim of IT @ 2010 is to learn from the achievements of the very best IT installations on the globe. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3517638 Thu, 29 Apr 2010 23:00:00 +0100 3517638 Sales Force Effectiveness USA 2010 http://www.medworm.com/index.php?rid=3513641&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1201%2F28%2F 17-18 May 2010, Princeton, NJ, USA. SFE USA is a premier conference for pharma. Learn how to develop a winning sales strategy from pharma leaders. 10 Industry VPs will deliver sessions on healthcare reform, customer-centric models, and CRM tools. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3513641 Wed, 28 Apr 2010 23:00:00 +0100 3513641 Boehringer Ingelheim grows faster than the pharmaceutical market http://www.medworm.com/index.php?rid=3513640&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1202%2F31%2F Boehringer Ingelheim continued to grow in 2009, increasing its net sales by 9.7% to EUR 12.7 billion (2008: EUR 11.6 billion). This was announced by the company at its Annual Press Conference. Even without taking into account positive currency effects, growth was once again above the average growth for the worldwide pharmaceutical market, at 6.7%. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3513640 Wed, 28 Apr 2010 23:00:00 +0100 3513640 Roche Group sustained its strong sales growth in the first three months of 2010 http://www.medworm.com/index.php?rid=3509969&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1199%2F31%2F Group sales grew 9% in local currencies (6% in Swiss francs; 15% in US dollars) to 12.2 billion Swiss francs. The Pharmaceuticals Division's sales increased 10% in local currencies (6% in Swiss francs; 15% in US dollars) to 9.7 billion Swiss francs, maintaining its above-market growth. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3509969 Tue, 27 Apr 2010 23:00:00 +0100 3509969 Despite Concern, Americans Aren't Protecting Themselves Against Diabetes http://www.medworm.com/index.php?rid=3509968&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1200%2F27%2F Diabetes affects more than 23 million people in the United States today and another 54 million people have pre-diabetes, according to the Centers for Disease Control and Prevention (CDC). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3509968 Tue, 27 Apr 2010 23:00:00 +0100 3509968 Novartis healthcare portfolio generates strong growth in first quarter of 2010 http://www.medworm.com/index.php?rid=3506685&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1196%2F31%2F Novartis delivered a strong performance in the first quarter of 2010 - particularly the rapid expansion of recently launched products and important regulatory approvals achieved for new medicines and vaccines - as the Group made progress with a sharp focus on innovation, growth and productivity. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3506685 Mon, 26 Apr 2010 23:00:00 +0100 3506685 Study Reveals Exciting Physician Growth in the Areas of Mobile, Social, and Online Access http://www.medworm.com/index.php?rid=3506684&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1197%2F27%2F Physicians show continued adoption of mobile and social media for professional purposes, as well as increasing dependency on digital resources at the point of care, according to pharmaceutical and healthcare market research company Manhattan Research's latest Taking the Pulse® study of over 2,000 U.S. physicians. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3506684 Mon, 26 Apr 2010 23:00:00 +0100 3506684 Novo Nordisk's operating profit increased by 15% in the first quarter of 2010 http://www.medworm.com/index.php?rid=3506683&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1198%2F31%2F Reported operating profit increased by 15% to DKK 4,382 million. Adjusted for the impact from currencies, operating profit in local currencies increased by around 20%. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3506683 Mon, 26 Apr 2010 23:00:00 +0100 3506683 World Bank and Pfizer Announce Initiative to Help Improve Healthcare Delivery http://www.medworm.com/index.php?rid=3503848&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1194%2F30%2F The World Bank and Pfizer Inc. announced they will collaborate to improve the healthcare infrastructure, specifically the supply chain, in developing countries, starting with Africa. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3503848 Sun, 25 Apr 2010 23:00:00 +0100 3503848 Global E-Health Forum - Hamburg 2010 http://www.medworm.com/index.php?rid=3503847&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1195%2F28%2F 25-26 October 2010, Hamburg, Germany. The Global E-Health Forum has been conceived to create a unique opportunity to discuss potential solutions in patient-centric health management. The past three Baltic Conferences on E-Health (2007-2009) have generated considerable interest in countries far beyond the Baltic Sea Region. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3503847 Sun, 25 Apr 2010 23:00:00 +0100 3503847 Superior efficacy of Victoza® (liraglutide) compared to Januvia® (sitagliptin) http://www.medworm.com/index.php?rid=3503849&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1193%2F29%2F The Lancet published online the results of the first study comparing the once-daily human GLP-1 analogue, Victoza® (liraglutide) with a DPP-4 inhibitor, Januvia®. The 26-week trial showed that Victoza® produced significantly greater reductions in HbA1c, fasting plasma glucose (FPG) and body weight than Januvia®, with similar or better overall treatment satisfaction.[1] (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3503849 Thu, 22 Apr 2010 23:00:00 +0100 3503849 Pfizer Discontinues Phase 3 Trial of Sutent® in Advanced Hepatocellular Carcinoma http://www.medworm.com/index.php?rid=3496382&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1192%2F29%2F Pfizer Inc. announced the discontinuation of the SUN 1170 Phase 3 open-label study of Sutent(r) (sunitinib malate) in advanced hepatocellular carcinoma (HCC), or liver cancer. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3496382 Thu, 22 Apr 2010 23:00:00 +0100 3496382 The Lancet publishes new data demonstrating the superior efficacy of Victoza® (liraglutide) compare http://www.medworm.com/index.php?rid=3496381&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1193%2F29%2F The Lancet published online the results of the first study comparing the once-daily human GLP-1 analogue, Victoza® (liraglutide) with a DPP-4 inhibitor, Januvia®. The 26-week trial showed that Victoza® produced significantly greater reductions in HbA1c, fasting plasma glucose (FPG) and body weight than Januvia®, with similar or better overall treatment satisfaction.[1] (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3496381 Thu, 22 Apr 2010 23:00:00 +0100 3496381 Amgen's First Quarter 2010 Revenue Increased 9 Percent to $3.6 Billion http://www.medworm.com/index.php?rid=3496383&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1191%2F31%2F Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.30 for the first quarter of 2010, an increase of 20 percent compared to $1.08 for the first quarter of 2009. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3496383 Wed, 21 Apr 2010 23:00:00 +0100 3496383